Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The phase 2 dose-ranging trial (NCT02970942) included 320 individuals with histologically proven MASH and hepatic fibrosis F1-F3, randomizing them 3:3:3:1:1:1 to daily subcutaneous administration of semaglutide 0.1, 0.2, or 0.4 mg, or placebo for 72 weeks [18]
This master chart provides your starting point
GLP Monitor: AI GLP-1 Tracker is your supportive digital companion, designed to take the guesswork and stress out of your GLP1 journey
P., Bounous, G., Baruchel, S., Lee, T
US$ 27.23
US$ 26.43
US$ 24.67
US$ 21.33
US$ 20.58
US$ 27.97
US$ 22.04
US$ 22.50
